Fate Therapeutics Presents Updated Clinical Data From Its Ongoing Phase 1 Trial Evaluating Its Ft819 Off-The-Shelf iPSC-derived Car T-cell Program In Systemic Lupus Erythematosus And Unveiled New Preclinical Data From Next-Gen. Off-The-Shelf iPSC-Derived Car T-cell Programs For Hematologic Malignancies And Autoimmune Diseases At 2025 American Society Of Hematology Annual Meeting

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated

First ex-U.S. SLE patient treated with FT819 expands enrollment capacity and supports unique ability of FT819 for broad, on-demand patient accessibility

Preclinical studies show FT836 chimeric antigen receptor (CAR) T cells uniquely targeting stress antigens MICA/B, combined with daratumumab, provide a comprehensive approach to treatment of multiple myeloma

FT839 CAR T cells demonstrate the unique ability to treat a wide range of B-cell malignancies and autoimmune diseases through dual-CAR CD19/CD38 targeting without the need of conditioning chemotherapy in various preclinical models; combination with monoclonal antibodies or T-cell engager further expands targeting capacity